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The porcine reproductive and respiratory syndrome virus (PRRSV)
causes porcine reproductive and respiratory syndrome in swine
population. The disease is characterized by respiratory distress in
piglets and late term reproductive failure and associated complications
in pregnant sows (Snijder and Spaan, 2007). This disease was ﬁrst
reported in the United States and later in the Netherlands and other
parts of the world (Benﬁeld et al., 1999; Paton et al., 1991). The PRRSV
belongs to the order Nidovirales, family Arteriviridae and genus
Arterivirus. Other related viruses of family Arteriviridae are equine
arteritis virus (EAV), lactate dehydrogenase-elevating virus (LDHV) and
simian haemorrhagic fever virus (SHFV) (Snijder and Meulenberg,
1998). Based on their geographic location and genome sequences,
PRRSVs are classiﬁed as European (type I) or North American (type II)
genotypes. These two genotypes share approximately 60% genome
similarity (Forsberg, 2005; Hanada et al., 2005).
PRRSV has a positive stranded RNA genome of approximately 15.4
kilobases and contains nine open reading frames (ORFs). ORF1a andORF1b synthesize polyproteins which are processed to produce 13–14
non-structural proteins (NSPs) (Meulenberg, 2000; van Aken et al.,
2006). The NSPs are involved in viral genome replication and poly-
protein processing (Kroese et al., 2008; Meulenberg, 2000; Snijder and
Meulenberg, 1998). Several of the NSPs, namely, the NSP 1α, NSP 1β,
NSP 2,NSP 4, andNSP 11 are also involved in IFN and TNF-α antagonism
(Beura et al., 2010; Chen et al., 2010; Kim et al., 2010; Subramaniam et
al., 2010).ORFs2 to7 encode seven structural proteins, fourofwhichare
glycoproteins [GP2 (previously called GP2a), GP3, GP4, and GP5] that
are present on the virion envelope. The protein E (or 2b) and the
membrane protein (M) are also present on the envelope, but are not
glycosylated. The GP5 is present on the virion envelope in abundant
amounts and therefore is called the major envelope glycoprotein
whereas the GP2, GP3 and GP4 are calledminor envelope glycoproteins
as they are present in less abundant amounts. The GP2, GP3 and GP4
interactwith each other andGP5 interactswith both GP4 andMprotein
(Das et al., 2010;Mardassi et al., 1996). These interactions are critical for
formation of multiprotein complexes that are required for assembly of
infectious PRRSVs (Wissink et al., 2005). Additionally, GP5 and M
proteins interact to form heterodimers (Mardassi et al., 1996). GP2 and
GP4 proteins have been shown to speciﬁcally interact with CD163
molecule (Das et al., 2010), a receptor for PRRSV entry (Calvert et al.,
2007; Van Gorp et al., 2008).
The N-glycosylation of proteins of many different families of
viruses have been shown to be important for tissue tropism, receptor
Fig. 1. PRRSV genome organization and the three minor envelope glycoproteins.
(A) Schematic representation of PRRSV genome organization. The ORFs are shown as
solid rectangles from 5' to 3' end with their names shown. The 5' cap is shown with a
dark-ﬁlled circle; the ribosomal frame-shifting position between ORF1a and ORF 1b is
shown with a gray-ﬁlled circle. (B) Linear structures of various minor envelope
glycoproteins (GPs). The length of each of the proteins in amino acids and the potential
N-glycosylation sites are shown. The length of the predicted signal sequences (SS) and
transmembrane regions (TM)of the proteins are shownon top of the rectangles. N, amino-
terminus; C, carboxy terminus.
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and egress, immune evasion, and pathogenesis (Beasley et al., 2005;
Daniels et al., 2003; Fournillier et al., 2001; Hanna et al., 2005;
Luftenegger et al., 2005; Mondotte et al., 2007; Shi et al., 2005; Shi and
Elliott, 2004; Vigerust and Shepherd, 2007). The N-glycosylation of
simian immunodeﬁciency virus, human immunodeﬁciency virus,
Bunyamwera virus, hepatitis C virus, and Ebola virus not only
promotes viral replication and infectivity, but also provides a glycan
shield against host neutralizing antibodies and thereby facilitates
virus spread and inﬂuence pathogenic outcome (Lin et al., 2003;
Reitter et al., 1998; Scanlan et al., 2007; Shi et al., 2005; Vigerust and
Shepherd, 2007; Wei et al., 2003). Previous studies have shown that
glycan addition at certain sites in GP5 protein of PRRSV is required for
infectious virus production (Ansari et al., 2006; Wissink et al., 2004);
glycan addition at other sites in GP5 help the virus escape
neutralization by the host antibodies through “glycan shielding”
mechanism (Ansari et al., 2006). Additionally, hypoglycosylation of
GP5 was also shown to induce signiﬁcantly higher neutralizing
antibody response in PRRSV-infected pigs (Ansari et al., 2006). The
role of glycosylation of the minor envelope GPs in infectious PRRSV
production and immune response has not been examined yet. Only
one report using the Lelystad virus (type I PRRSV) showed that the
two N-glycosylation sites of GP2 are dispensable for infectious virus
production (Wissink et al., 2004).
In this communication, we have performed studies to examine
the role of glycosylation of the minor envelope GPs of PRRSV, the
GP2, GP3, and GP4 proteins in infectious virus generation, the effect
of glycosylation on interaction with the receptor CD163 and if the
host neutralizing antibody response can be modulated by hypogly-
cosylation of the GPs. Our results show that in contrast to the type I
Lelystad virus, glycosylation at N184 of GP2 protein of the FL12 virus
(a type II PRRSV) is required for infectious virus production. Addi-
tionally, glycosylation at residues N42, N50 and N131 of GP3 pro-
tein of PRRSV is shown to be critical for infectious virus production.
While none of the single glycosylation site mutations in GP4 had
any effect on infectious PRRSV recovery, introduction of two or more
mutations was found to be lethal. The studies also show that
glycosylation of GP2 and GP4 proteins is required for efﬁcient
interaction with CD163. The results further reveal that glycosylation
of the three minor envelope glycoproteins does not appear to play
any role in the neutralizing antibody response mounted by the
infected animals.
Results
Expression of minor envelope glycoproteins in transiently transfected
and virus-infected cells
PRRSV has four envelope glycoproteins, GP2, GP3, GP4, and GP5
encoded by the open reading frames (ORF) 2a, 3, 4, and 5, respectively
(Fig 1A). Bioinformatic analyses using SignalP 3.0 and DAS TMpred
programs suggested that each of these GPs has a cleavable signal
sequence (SS) and a transmembrane (TM) domain, which are shown
in Fig. 1B. The calculatedmolecularweights of the unglycosylated GP2,
GP3, and GP4 following signal sequence cleavage are approximately
25 kDa, 26 kDa, and 17 kDa, respectively. The NetNGlyc 1.0 program
also predicted several N-linked glycosylation sites in these proteins,
which are schematically depicted in Fig. 1B. In the current study, we
wanted to examine the role of glycosylation of the minor envelope
glycoproteins in infectious progeny production. Examination of
potential glycosylation sites in these proteins of the infectious clone
derived FL12 virus suggested that GP2 has two potential glycan
addition sites at positions 178 and 184; GP3 has seven such sites at
positions 29, 42, 50, 131, 152, 160, and 195; and GP4 has four sites at
positions 37, 84, 120, and 130 (Fig. 1B). These sites are somewhat
conserved in strains of North American type II PRRSVs. We hadpreviously shown that glycosylation of GP5 at amino acid position 44 is
required for infectious virus production (Ansari et al., 2006). For the
North American type II PRRSV and in particular, for the FL12 virus, it is
not known which of the potential glycosylation sites are indeed used
for glycan addition in these proteins.
Toward this goal, we ﬁrst examined expression of the individual
minor envelope GPs in cells transfected with plasmids encoding
these proteins as well as in cells infected with PRRSV. In MARC-145
cells infected with infectious clone (FL12) derived virus or in baby
hamster kidney-21 (BHK-21) cells transfected with GP2-encoding
plasmid, the mature form of GP2 (identiﬁed by a white dot) was
synthesized as an approximately 32 kDa protein (Fig. 2A). However,
under both experimental conditions, the major species of the protein
migrated with a molecular mass of approximately 29–30 kDa. This
protein species is most likely the GP2 protein having N-glycan
addition in only one of the two predicted sites. Thus, it appears that
glycan addition at one site in GP2 is more efﬁcient or that the addition
of glycan at the second site is slow. Unlike GP2 protein, the major
species of GP3 synthesized in virus-infected cells or in plasmid-
transfected cells corresponded to a 42 kDa protein (Fig. 2B). However,
signiﬁcantly reduced amounts of a number of faster migrating protein
species could also be detected. The identity of these proteins is
unknown but could be non-speciﬁc cellular proteins immunopreci-
pitated by the GP3 antibody. The GP4 protein synthesized in PRRSV-
infected cells was detected as a single major species of approximately
29 kDa but in addition to this protein, smaller proteins, possibly
representing partially glycosylated forms of GP4 or some cellular
proteins, were also detected in GP4 encoding plasmid-transfected
cells (Fig. 2C).
The observation that single and multiple glycosylation mutant
proteins co-migrated with the smaller protein species (see Figs. 3A
and 5A) and the fact that endoglycosidase H digestion of the proteins
resulted in detection of single protein species (see Das et al., 2010)
suggest that the smaller species are partially glycosylated forms of the
proteins and argue against the possibility that they are the
degradation products of the full-length proteins.
Fig. 2. Expression of minor envelope GPs in virus-infected and plasmid-transfected cells. MARC-145 cells were mock-infected or infected with wt FL12 virus (MOI of 1) or BHK-21
cells were infected with vTF7-3 virus and subsequently transfected with an empty vector or the vector encoding individual envelope GPs as described in materials and methods. The
FL12 virus-infected MARC-145 cells were radiolabeled with 35S after 48 hpi (lanes 1 and 2) whereas the transfected BHK-21 cells were radiolabeled with 35S after 16 h post-
transfection (lanes 3 and 4). The radiolabeled proteins from the cell extracts were immunoprecipitated with anti-GP2 (A), anti-GP3 (B) or anti-GP4 (C) antibody, resolved in SDS–
10% PAGE and detected by ﬂuorography. The fully glycosylated GPs are denoted by white dots whereas the partially glycosylated proteins are denoted by black dots. The relative
mobilities of the molecular mass markers in kDa are shown on the left of each panel.
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for infectious virus recovery
The GP2 protein of European type I PRRSV contains two N-
glycosylation sites and it has been shown that glycan addition at theseFig. 3. N-glycosylation of residue N184 of GP2 is required for infectious virus production.
(lane 1), vector encoding GP2 (lane 2) or its N-glycosylation site mutants (lanes 3–5). Cells
immunoprecipitation with anti-FLAG antibody, resolved in SDS-12%PAGE and detected by
partially glycosylated or unglycosylated forms are indicated by black dots on the left of lan
(B) Representative multi-step growth kinetics of wt FL12 and FL12-N178A mutant virus. (C
passage FL-N178A virus or wt FL12 (lane 4) virus. MARC-145 cells were infected with the p
methods, the proteins were immunoprecipitated with anti-GP2 antibody, resolved by SDS–1
recovered from sera after 21 days post-inoculation of piglets with FL12-N178A or wt FL12 viru
except that the sera collected from animals that were sham-infected (lane 1), infected with F
145 cells. The relative mobilities of molecular mass markers in kDa are shown on the left ssites is dispensable for infectious virus production (Wissink et al.,
2004). The GP2 of North American type II virus (FL12 virus) has two
predicted glycosylation sites at positions 178 and 184. To examine if
one or both of these sites are used for glycan addition and whether
glycosylation of these sites are required for infectious virus(A) BHK-21 cells were infected with vTF7-3 virus and transfected with empty vector
were radiolabeled for 4 h at 16 h post-transfection, and the proteins were analyzed by
ﬂuorography. The fully glycosylated wt GP2 is indicated by white dot whereas, the
e 2. Various glycosylated forms of GP2 are shown on the right side of the ﬂuorogram.
) Detection of mutant GP2 protein in cells infected with 2nd (lane 2) or 10th (lane 3)
assaged virus at an MOI of 1, cells were radiolabeled as described in the materials and
0% PAGE and detected by ﬂuorography. (D) Detection of GP2 in cells infected with virus
s. The experiment was performed similarly as described for virus-infected cells in Fig. 2,
L12-N178A virus (lane 2), or FL12 virus (lane 3) were used for infection of naive MARC-
ide of each of the ﬂuorograms.
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replaced with alanine (A) residues to generate two single (N178A and
N184A) and one double (N178/184A) glycosylation mutants. These
mutations were generated using a carboxy terminal FLAG-tagged GP2
construct. In cells transfected with plasmids encoding the mutants,
synthesis of various mutant proteins could be readily detected
(Fig. 3A). Although the FLAG-tagged wt GP2 migrated as a 33 kDa
protein, the GP2-FLAG-N178A and GP2-FLAG-N184A proteins migrat-
ed with a molecular weight of around 31 kDa (Fig. 3A, lanes 3 and 4),
the GP2-FLAG-N178/184A double glycosylation mutant protein
migrated with a molecular mass of 28 kDa (Fig. 3A, lane 5), suggesting
that both the glycosylation sites are used for glycan addition in GP2.
The mutant GP2 coding sequences (without FLAG-tag) were then
inserted into full-length infectious clone FL12 (Truong et al., 2004)
genome and virus rescue was performed by electroporation of in vitro
transcribed RNA into MARC-145 cells. Four to ﬁve days after
electroporation, cytopathic effect (CPE) was only observed in cells
transfected with RNA from FL12-GP2-N178A construct but not in cells
transfected with RNA from either FL12-GP2-N184A or FL12-GP2-
N178/184A mutant constructs. Multiple attempts using at least two
independent clones to recover virus from FL12-GP2-N184A or FL12-
GP2-N178/184Amutant construct failed, indicating that glycan addition
at position 184 in GP2 is critical for recovery of infectious virus.
Following rescue of FL12-N178A mutant virus, examination of multi-
step growth kinetics of themutant virus showed no apparent difference
from that of the wt virus (Fig. 3B), suggesting that glycosylation at
position 178 has no effect on growth of the mutant virus in MARC-145
cells.
Since no differences were observed in growth kinetics of the
mutant virus, we examined if the mutant virus still maintained the
N178A amino acid substitution in the genome. The presence of correct
mutation in FL-N178A recovered virus was conﬁrmed by RT-PCR
ampliﬁcation and sequencing of the entire GP2 coding region.
Furthermore, no other mutations were detected in GP2. In cells
infected with the passage 2 and passage 10 mutant viruses, the GP2-
N178A protein migrated with a mobility that correlated with loss of
one glycosylation site (Fig. 3C). The GP2 proteins in these mutant
virus-infected cells (lanes 2 and 3) clearly migrated faster than the
GP2 protein synthesized in wt FL12 virus-infected cells (lane 4),
demonstrating the stability of the mutant virus under in vitro passage
conditions. Similarly, the cells infected with the virus present in sera
collected on 21 days post-inoculation from FL12-N178A infected
piglets also synthesized GP2-N178A protein which migrated with a
mobility that correlated with loss of one glycan site (Fig. 3D, lane 2) as
compared to GP2 synthesized in cells infected with the virus present
in sera collected from piglets infected with wt FL12 virus (Fig. 3D, lane
3). These results suggest that the mutant FL12-N178A virus is stable
under in vitro and in vivo growth conditions.
Glycosylation at several sites in GP3 is critical for infectious virus
production
The GP3 protein contains seven potential N-linked glycosylation
sites (Fig. 1B). To determine which of the sites are used for glycan
addition, we mutated N to A at these sites. The wt or mutant GP3
sequences were cloned and expression of the proteins was examined
in cells transfected with the plasmids encoding the proteins. While
the wt GP3 migrated with a molecular weight of approximately
42 kDa (Fig. 4A, lane 2), the proteins expressed from the single
glycosylation mutant clones (GP3-N29A, GP3-N42A, GP3-N50A, GP3-
N131A, GP-3N152A, GP3-N160A) migrated with a molecular weight
of approximately 39–40 kDa (lanes 3–8). On the other hand, one
mutant construct GP3-N195A produced GP3 that co-migrated with wt
GP3 (lane 9). These results indicate that six sites at positions N29,
N42, N50, N113, N152, and N160 are used for glycan addition whereas
N195 is not used for glycosylation.We subsequently introduced the individual glycosylation site
mutants of GP3 into the FL12 infectious clone to rescue infectious
PRRSV. Upon transfection of MARC-145 cells with in vitro transcripts
from each of the clones, CPE was observed in cells 5 days after
electroporation of RNA from FL12-GP3-N29A, FL12-GP3-N152A and
FL12-GP3-N160A, indicating successful recovery of these mutant
viruses. However, following multiple repeat experiments using two
independent clones, viruses encoding mutations at the positions N42,
N50 or N131 could not be recovered, suggesting that glycan addition
at these sites is essential for infectious particle formation. The
recovered mutant viruses demonstrated similar multi-step growth
kinetics as the wt PRRSV (Fig. 4B), although the FL12-GP3-N29A and
FL12-GP3-N152A viruses grew reproducibly to similar or slightly
higher titers than the wt FL12 whereas the titers of FL12-GP3-N160A
virus were lower. All the three viruses were found to be stable for at
least 10 passages in MARC-145 cells as they were found to retain the
inserted mutation and synthesized GP3 in infected cells with a
mobility that correlatedwith the loss of one glycosylation site (Fig. 4C,
lanes 3–5). These results show that glycosylation at amino acid
positions 42, 50 and 131 of GP3 is important for infectious virus
productionwhereas glycan addition at residues 29, 152, and 160 is not
required.
Since individual glycan addition at residues 29, 152, and 160 was
found to be dispensable for infectious virus recovery, we next
examined whether mutations at two or more of these sites would
still lead to virus recovery. To address this, we simultaneously
mutated these residues in various combinations to obtain GP3-N29/
152A, GP3-N29/160A, GP3-N152/160A, and N29/152/160A mutant
proteins. All the four mutant proteins were expressed in transfected
BHK-21 cells at levels similar to the wt or single-site mutants and
possessed electrophoretic mobility that correlated with the loss of
two or three glycan moieties (Fig. 4D) Infectious viruses encoding
each of the glycosylation mutant GP3 could be readily recovered from
cells transfected with corresponding RNA. The recovered viruses were
found to retain the incorporated mutation even after 10 passages in
MARC-145 cell (data not shown). In multi-step growth kinetics
studies, the triple mutant virus (FL12-GP3-N29/152/160A) grew
slowly and to signiﬁcantly reduced titers as compared to the
double-mutant viruses (Fig. 4E), indicating that glycosylation of at
least two of these sites is needed for optimal generation of infectious
viruses. The triple mutant virus (FL12-GP3-N29/152/160A) growth
could only be detected at 96 hpi, and the virus growth decayed
signiﬁcantly by 120 hpi. Also, in FL12-GP3-N29/152/160A virus-
infected cells, the onset of CPE was signiﬁcantly delayed. The GP3
proteins synthesized in these mutant virus-infected cells migrated
with molecular sizes consistent with loss of two or three glycan
moieties and also migrated faster than the GP3 protein synthesized in
FL12 virus-infected cells (Fig. 4F). Overall, these results show that
simultaneous loss of glycans at residues 29, 152 and 160 affected
optimal virus growth and infectious virus production.
Mutation of individual glycosylation sites in GP4 does not affect
infectious virus recovery but multiple mutations are lethal
GP4 protein has four predicted N-glycosylation sites at positions 37,
84, 120, and 130 (Fig. 1B). These sites were mutated individually to
obtain the clones GP4-N37A, GP4-N84A, GP4-N120A, and GP4-N130A.
In plasmid-transfected cells, the proteins encoded in these mutant
clones migrated as approximately 26 kDa proteins, as compared to the
wt GP4 that possessed an electrophoretic mobility of 29 kDa (Fig. 5A).
This result indicated that all the four potential glycosylation sites in GP4
are indeedused for themodiﬁcation. Todetermine if the glycan addition
at all four sites is necessary for recovery of infectious PRRSV, we
introduced themutations in GP4 coding regions of infectious clone FL12
and found that PRRSVs encoding the single glycosylation site mutant
GP4 could be readily recovered. However, insertion of mutations at
Fig. 4. Glycan addition at several sites in GP3 is required for infectious virus production. (A) BHK-21 cells were infected with vTF7-3 and transfected with pGEM3 (empty vector,
lane 1), the plasmid encoding wt GP3 (lane 2) or its glycosylation site mutants (lanes 3–9). Cells were radiolabeled for 4 h at 16 h post-transfection, and the proteins were analyzed
by immunoprecipitation with anti-GP3 antibody, resolved in SDS-12%PAGE and detected by ﬂuorography. (B) Representative multi-step growth kinetics of viruses encoding GP3
single-site glycosylation mutants. (C) Synthesis of GP3 protein in cells infected with the wt FL12 or GP3 mutant viruses. The experiment was performed with passage 10 mutant
viruses. (D) Expression of GP3 double and triple N-glycosylation mutants in BHK-21 cells. The experiment was performed as described in panel A and various glycosylated forms of
the protein are identiﬁed on the right. (E) Representative multi-step growth kinetics of viruses encoding GP3 double and triple glycosylation mutants. (F) Expression of wt ormutant
GP3 in cells infected with wt FL12 or mutant viruses encoding double or triple glycosylation mutant GP3 viruses. Tenth passage virus was used and the experiment was performed as
described in panel C. The relative mobilities of molecular mass markers in kDa are shown on the left side of each of the ﬂuorograms.
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step growth kinetics analysis (Fig. 5B) as well as infectious virus yield
assays indicated that all themutant viruses had higher titers than thewt
virus. Unlike thewt FL12 virus, which typically grows to its highest titer
at 72 hpi, the GP4 single mutant viruses grew to their highest titers at
48 hpi. At this time point, the titers of FL12-GP4-N120A and FL12-GP4-
N130Amutant viruseswere almost10- to50-fold greater than that ofwt
FL12. The reason(s) for the better growthof thesemutantviruses arenot
known at this time but could be related to more favorable interactions
with the virus receptor in MARC-145 cells or more efﬁcient formation
of multi-glycoprotein complex, which is required for infectious virus
production.Fig. 5. GP4 proteins with mutation of single glycosylation sites do not affect infectious virus
experiment was conducted as described in Fig. 4A. Proteins were detected using anti-GP4
partially glycosylated forms of the proteins are identiﬁed by black dots, on the left side of lane
the ﬂuorogram. (B) Representative multi-step growth kinetics of GP4 single glycosylation m
GP4 proteins in cells infected with tenth passage GP4 glycosylation mutant viruses. The exIn the MARC-145 cells infected with the single glycosylation site
mutant viruses, GP4 proteins migrated with a mobility that correlated
with the loss of one glycosylation site (Fig. 5C, lanes 2–5).
Furthermore, in MARC-145 cells infected with sera collected from
pigs at 21 days post-inoculation, GP4 protein from the four GP4 single
glycosylation mutants migrated with mobility faster than that of the
wt protein (data not shown). Sequence analysis of the viral genomes
isolated from the sera of infected pigs or from the culture super-
natants of in vitro passaged virus showed that the introduced
mutations were present and no other additional mutations were
detected in the GP4 coding regions, indicating that the mutant viruses
were stable under in vivo and in vitro passage conditions.production. (A) Expression of GP4 single glycosylation mutants in transfected cells. The
antibody. The fully glycosylated GP4 proteins is identiﬁed by white dot, whereas the
2. The relative mobilities of molecular massmarkers in kDa are shown on the left side of
utant viruses. The experiment was performed as described in Fig. 3B. (C) Expression of
periment was conducted as described in Fig. 4C using anti-GP4 antibody.
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the receptor, CD163
Wehad previously shown that porcine CD163, a receptor for PRRSV,
interacts speciﬁcally with GP2 and GP4 proteins of PRRSV (Das et al.,
2010). Therefore, we wanted to examine if glycosylation of these two
proteins plays any role in their interactionswith the CD163molecule by
co-IP assays as described previously (Das et al., 2010). The receptor
CD163 was co-expressed with the FLAG-tagged wt or glycosylation
mutant GP2 proteins in plasmid-transfected cells. The interacting
protein complexes were co-immunoprecipitated with anti-FLAG poly-
clonal antibody or anti-CD163 monoclonal antibody and resolved in
SDS–10% PAGE gel. By using anti-FLAG antibody, CD163 could be readily
detected by immunoprecipitation of cell lysates co-expressing CD163
andGP2-FLAG,GP2-FLAG-N178AorGP2-FLAG-N184Aproteins (Fig. 6A,
lanes 9–11). But, CD163molecule could not be detectedwhen itwas co-
expressed with completely unglycosylated form of GP2 (GP2-FLAG-
N178/184A) protein (Fig. 6A, lane 12). When we carried out the
converse experiment using anti-CD163 monoclonal antibody, the
results showed that CD163 antibody could detect the wt and single
glycosylation mutant GP2 proteins, but none to very low levels of
completely unglycosylated GP2 was detected (data not shown). These
results suggest that glycosylation of at least one site in GP2 protein is
necessary for efﬁcient interaction with the receptor CD163.
A similar study was performed to examine the role of N-
glycosylation of GP4 protein in its interaction with CD163 (Fig. 6B).
Since the single glycosylation mutant GP4 supported recovery of
infectious PRRSVs, it was presumed that these mutants will interact
with CD163. Therefore, in these studies, we used only one double
mutant (GP4-N37/84A) and the quadruple mutant (GP4-N37/84/120/
130A) that synthesizes the completely unglycosylated form of GP4
protein for their interactions with CD163. In cells co-expressing CD163
and the wt or themutant GP4 proteins, interaction between CD163 and
GP4 was found to be dependent on the extent of glycosylation of GP4.
Unlike the wt GP4, which interacts well with CD163 (Das et al., 2010),
the GP4mutantwith only two glycanmoieties interacted less well with
CD163 (Fig. 6B, lane 8). Further, the interaction of the unglycosylated
GP4 with CD163 was very inefﬁcient as only a very small amount of
CD163 could be immunoprecipitated with GP4 antibody (Fig. 6B,
lane 9). Similar results were obtained in multiple repeat experiments
using these mutants as well as using the other double glycosylation
mutantGP4proteins, indicating that the extentof glycosylationofGP4 is
critical for efﬁcient interaction with CD163.Fig. 6. Glycosylation of GP2 and GP4 proteins is required for efﬁcient interaction with CD1
infected with vTF7-3 virus and transfected with empty vector (lanes 1 and 3) or the plasmid e
indicate without or with the plasmid shown on the left. The cells were radiolabeled and imm
resolved in SDS–10% PAGE and detected by ﬂuorography. CD163 and different glycosylated
possibly the signal sequence cleaved unglycosylated GP2. (B) Examination of CD163 interac
panel A, proteins were immunoprecipitated with antibodies shown below the lanes. − an
mutants are identiﬁed on the left. The relative mobilities of the molecular mass markers inMutant PRRSVs encoding hypoglycosylated forms of minor GPs do not
induce enhanced neutralizing antibody response
We previously demonstrated that PRRSVs encoding hypoglycosy-
lated forms of the major envelope glycoprotein GP5 induced signiﬁ-
cantly higher levels of neutralizing antibody response in infected piglets
(Ansari et al., 2006). To determine if PRRSVs encoding hypoglycosylated
forms of the minor envelope GPs can also induce higher neutralizing
antibody response in infected animals, we used the wt FL12 or several
mutant viruses encoding hypoglycosylated minor GPs. Groups of four
21-day-old piglets were injected with the wt or the mutant viruses as
describedpreviously (Ansari et al., 2006). Following infection, serawere
collected from each animal at days 7 and 46 post-infection. Neutralizing
antibody titers in sera collected at days 7 and 46 post-infection were
measured using the ﬂuorescent focus neutralization assay as described
(Ansari et al., 2006; Wu et al., 2001). Results (not shown) revealed no
signiﬁcant differences in neutralizing antibody titers produced in wt or
mutant virus-infected animals, indicating that hypoglycosylation of any
of the minor envelope GPs do not induce higher neutralizing antibody
response in infected animals.Discussion
Viruses use host cell machinery for glycosylation of the viral
envelope proteins (Vigerust and Shepherd, 2007). PRRSV has four
envelope glycoproteins GP2, GP3, GP4, and GP5. Our previous study on
GP5 protein had shown that glycan addition at residue N44 is required
for infectious virusproductionwhereas glycans at residuesN34andN51
suppress host neutralizing antibody response in infected piglets (Ansari
et al., 2006). Those studies also revealed that PRRSVs encoding
hypoglycosylated forms of GP5 are exquisitely sensitive to neutraliza-
tion by antibodies and that the mutant viruses induce signiﬁcantly
higher amounts of neutralizing antibodies against homologous mutant
viruses as well as against wt PRRSV (Ansari et al., 2006). The current
study was undertaken to determine if glycosylation of the other
envelope glycoproteins, namely, the GP2, GP3, and GP4 play any role
in production of infectious virus, interactions with the cell surface
receptor, CD163, and in neutralizing antibody response by the host.
These studies led us to conclude that (i) glycan addition at N184 of GP2,
N42, N50, and N131 of GP3 is required for infectious virus production,
(ii) glycosylation of any three of the four sites in GP4 is necessary for
recovery of infectious PRRSV, (iii) optimal interactions with CD163 is63. (A) Examination of CD163 interaction with wt or mutant GP2. BHK-21 cells were
ncoding CD163 andwt GP2-FLAG or glycosylation mutant GP2-FLAG proteins.− and+
unoprecipitated with speciﬁc antibodies as shown below the lanes. The proteins were
forms of GP2 proteins are identiﬁed on the right. The band identiﬁed with an asterisk is
tions with wt or mutant GP4 proteins. The experiment was performed as described in
d + indicate without or with the plasmid shown on the left. CD163 and various GP4
kDa are shown on the right side of each panel.
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glycosylation of minor envelope proteins do not play any measurable
role in viral immune evasion against host neutralizing antibody
response or enhance host neutralizing antibody response.
Examination of GP2 expression in virus-infected cells and in plasmid-
transfected cells indicates that one of the two N-glycosylation sites is
preferentially glycosylated. However, with the use of individual
glycosylation site mutants, it was not possible to identify the site that is
preferentially glycosylated as the amount of monoglycosylated GP2 was
found to be similar in both of these mutants (Fig. 3A). It is plausible that
glycosylation at one sequon inGP2 inﬂuences glycosylation at the second
sequon, as has been observed for rabies virus G protein (Wojczyk et al.,
2005). It is unknown how glycosylation at one sequon affects glycan
addition at another sequon in the same protein. Studies addressing this
question have so far yielded conﬂicting results. Glycan addition at one
sequon in soluble rat CD4 did not inﬂuence glycan addition at the other
sequon (Ashford et al., 1993); insertion or deletion of novel or existing
sequons in the alpha subunit of human chorionic gonadotropin was
shown to have no effect on glycan addition at other sequons in the
protein (Furuhashi and Suganuma, 2003). In contrast, insertion of a novel
sequon at two distinct but closely located positions in human tissue
plasminogenactivatorhaddisparate effects onglycanaddition at another
site in the protein (Pfeiffer et al., 1994). Since it has been proposed that
the glycosylation site must be at least 75 codons upstream of the
termination site for efﬁcient glycan addition (Ruiz-Canada et al., 2009), it
is possible that oneof the two sites (N178orN184) inGP2passes through
the oligosaccharyl transferase active site on the ER membrane without
being efﬁciently glycosylated. Further studies will be required to gain a
better understanding of glycosylation of GP2 and how glycosylation at
one site affects glycan addition at the other site.
Our study has revealed that out of the seven predicted potential
glycosylation site in GP3, N195 is not glycosylated. The bioinformatics
analysis shows that this residue has an intracytoplasmic orientation,
perhaps making it unavailable for glycosylation by the host enzymes
in the lumen of the ER. Studies with prototype foamy virus had
revealed that the glycan addition site present on the signal peptide is
not glycosylated (Luftenegger et al., 2005). The results obtained from
our studies concur with the recent ﬁndings from the analysis of N-
glycoproteome (Zielinska et al., 2010), which suggests that the sites
that are glycosylated, always orient toward the lumen of the ER, Golgi,
lysosome, or peroxisome but not toward the cytoplasmic face.
The observation that glycosylation at N184 of GP2 is required for
infectious PRRSV production is intriguing. The FL12 virus used in our
study is a type II PRRSV. A previous study with GP2 protein of Lelystad
virus (type I PRRSV) showed that both the N-glycosylation sites in GP2
(N173andN179)aredispensable for infectiousvirusproduction(Wissink
et al., 2004). Therefore, these results indicate that there are differences in
the requirement for glycosylation ofGP2 for infectious virus production in
these two genotypes of PRRSV. Differences in the requirement of
glycosylation of GP5 proteins of these two types of viruses for infectious
virus production have also been demonstrated previously (Ansari et al.,
2006; Wissink et al., 2004). Thus, it appears that these two viruses may
have evolved to have different requirements for glycosylation of their GPs
for productionof infectious viruses.Whether suchdifferences exist for the
other GPs and whether these differences contribute to their growth and
pathogenic potential remains to be investigated.
Glycan addition at several sites (N42, N50, and N131) located at the
amino-terminal half of GP3 is required for infectious virus production.
Since glycosylation of residues located within the ﬁrst 50 residues at the
amino-terminus of a protein has been proposed to play critical roles in
proper folding of the nascent protein through interactions with the ER
chaperones (Helenius and Aebi, 2001), it is possible therefore, that
withoutglycans at thesepositions, theGP3adopts aprotein conformation
that is not favorable for infectious particle production. Alternatively, the
mutant may exhibit altered interactions with the other viral GPs in a
manner that affect multiprotein GP assembly required for infectiousparticles. Likewise, glycan addition at N184 of GP2 may be required for
proper folding of the protein or its interactions with the other GPs for
infectious virus production. Although individual mutations at any of the
glycosylation sites in GP4 were found to be dispensable, double
glycosylation mutations were lethal for infectious virus recovery. These
results further concur with studies from other viruses that by mutating
single ormultiple glycosylation sites in the viral GPs, proper folding of the
mutant protein is impaired in such a manner that affects infectious virus
assembly. Defects in protein folding, intracellular trafﬁcking, virion
assembly, or egress have been observed for a number of enveloped
viruses including inﬂuenza virus, Hantaan virus, Dengue virus and
Japanese encephalitis virus when their envelope glycoproteins were
mutated at the glycosylation sites (Kim et al., 2008; Mondotte et al.,
2007). It will be interesting to determine how the partially glycosylated
forms of the GPs affect interactions with other GPs of PRRSV. It is known
that the PRRSV GPs, when expressed individually, are glycosylated with
high-mannose sugars andare retained in theERwhereas invirus-infected
cells, theGPs formheteromultimers andare furtherprocessed in theGolgi
(Ansari et al., 2006;Wissink et al., 2004) for packaging in the virions. It is
then possible that the mutant viruses may have altered heteromultimer
formation and this may inﬂuence infectious progeny production.
The observation that single glycosylation site mutants of GP4 grew
consistently to higher titers than the wt virus is reminiscent of the
results with Sindbis virus (Knight et al., 2009), in which single
glycosylation mutations in the E2 glycoprotein resulted in viruses
with better replication characteristics. This was correlated with higher
afﬁnity of themutant viruses for binding to glycosaminoglycan heparan
sulfate for initial interaction with the host cell. Although the single
glycosylation mutant GP4 proteins did not bind to the PRRSV receptor
CD163with increased afﬁnity (data not shown), it is possible that these
mutant proteins fold in a manner that is more favorable for infectious
virus production as compared to the wt GP4. This could potentially be
achieved through increased interactions with other viral GPs, incorpo-
ration into viral envelope, and/or interactions with other host cell
molecules that mediate PRRSV entry and replication. Further studies
will be needed to determine how the single glycosylation mutant GP4
proteins enhance virus infectivity or virus production.
Our results indicate that glycan addition at the two sites in GP2may
have different role for the functions of the protein. While glycosylation
atN184 is required for infectious progenyproduction, glycan addition at
N178 is not required. On the other hand, GP2 interaction with CD163
requires glycosylation at any one of these two sites. The glycan addition
in GP4 may also have a similar role in its functions. Although infectious
virus could not be recovered with GP4 containingmutations at any two
of the four sites, oneof thedoublemutants tested in our study interacted
with CD163, albeit less efﬁciently.
Glycosylation of GP5 of PRRSV was previously reported to be
required for conferring protection against host neutralizing antibody
response (Ansari et al., 2006). The studies reported here reveal that
there is no such effect of glycosylation of GP2, GP3, and GP4 proteins on
protection against neutralizing antibody response and/or enhanced
induction of neutralizing antibodies. It may be due to the fact that these
three minor envelope glycoproteins are not abundantly expressed on
the surface of the virion. Alternatively, potentially ‘malleable glycan
shield’ asproposed forHIV-1 (Wei et al., 2003) could exist, inwhich case
the glycan moieties on GP5 may block access of the neutralizing
antibodies to the minor GPs even if they are unglycosylated. Glycan
shield generally requires co-operative packing of entire envelope
protein complex to prevent antibody access (Wei et al., 2003) due to
steric hindrance, thus preventing binding of a neutralizing antibody to
anepitope.Our results suggest that either these threeGPsdonot contain
PRRSVneutralizingepitopesor that theglycan shieldingmechanismsdo
not operate in these GPs. It should be noted, however, that the GP3 of
North American type I strains seem to possess neutralizing epitopes
(Jiang et al., 2007; Kim and Yoon, 2008; Yang et al., 2000). So the latter
possibility appears to be more likely.
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Cell cultures and viruses
Growth and maintenance of BHK-21 and MARC-145 (a derivative
of MA-104) cells have been described previously (Das et al., 2010).
Recovery of infectious clone derived FL12 wt and mutant PRRSVs was
described before (Truong et al., 2004). Preparation of stocks of
recombinant vaccinia virus (vTF7-3) expressing the bacteriophage T7
RNA polymerase (Fuerst et al., 1986) was described before (Ansari
et al., 2006).
Reagents and antibodies
The mMESSAGE mMACHINE ultra T7 kit for preparation of
transcripts in vitro was purchased from Ambion Inc. (Austin, TX).
The Pfu-turbo DNA polymerase enzyme was purchased from
Stratagene (La Jolla, CA). The monoclonal antibody SDOW17 against
the nucleocapsid (N) protein of type I PRRSV (Nelson et al., 1993) was
purchased from National Veterinary Services Laboratory (Ames,
Iowa). The monoclonal porcine CD163 antibody was purchased
from AbD Serotec (Raleigh, NC). Anti- FLAG polyclonal antibody was
purchased from Sigma-Aldrich. The anti-GP5 antibody was kindly
provided by Dr. Carl Gagnon (University of Montreal, Canada).
Polyclonal antibodies for GP2, GP3, and GP4 were reported before
(Das et al., 2010; de Lima et al., 2009). Secondary antibody Alexa
ﬂuor-488 goat anti-mouse immunoglobulin G (IgG) antibody was
purchased from Molecular Probes.
Plasmid construction
The intermediate vector carrying the sequences spanning the
structural protein coding region and the 3'-UTR from the infectious
clone pFL12 (Truong et al., 2004) has been described previously
(Ansari et al., 2006; Das et al., 2010). This intermediate vector wasTable 1
Primers used in this study.
Primer name Primer nu
GP2-EcoRI-For ATATATGA
GP2-SphI-Rev ATATATGC
GP2-NheI-For ATATGCTA
GP2-FLAG-EcoRI-Rev ATATGAAT
GP2-N178A For CATGACAG
GP2-N184A For GTAACCAT
GP2-N178/184A For CATGACAG
GP3-EcoRI-For ATATAGA
GP3-BamHI-Rev TATATGGA
GP3-N29A-Rev CAGTACG
GP3-N42A-Rev GAGTTCG
GP3-N50A-For TCCTTCGA
GP3-N131A-For GGGATAG
GP3-N152A-For CGACGGG
GP3-N160A-For CGTCATGA
GP3-N195A-For GTTGGTTT
GP4-EcoRI-For ATATAGA
GP4-BamHI-Rev TATATGGA
GP4-FLAG-BamHI-Rev TATATGGA
GP4-N37A-Rev CGGTAGT
GP4-N84A-For CCCGTGTA
GP4-N120A-Rev GATGCCTG
GP4-N130A-Rev CGTAGCTG
GP5-EcoRI-For GCCGGAA
GP5-Myc-XhoI-Rev ATATATCT
pBR131-For CTGGATG
FL12-12816-For GGGGCAA
FL12-13177-For CTACCAAC
FL12-13465-Rev CTGTGATG
FL12-14473-Rev GTCGGCCG
Primer sequences are in the 5' to 3' direction. Restriction enzyme sites are underlined. Theused for subcloning of mutants of GP2, GP3, and GP4 into pFL12
infectious clone. Additionally, the coding regions of the individual GPs
were ampliﬁed by polymerase chain reaction (PCR) and cloned in
pGEM3 vector (Promega Biotech, Madison, WI) under the control of
T7 RNA polymerase promoter. Glycosylation site mutants [changing
asparagine (N) to alanine (A) residue] of various GPs were generated
by the megaprimer-based PCR approach (Sarkar and Sommer, 1990)
using the primers described in Table 1 and either the intermediate
vector or the vector carrying the individual GPs. The coding regions of
the GPs harboring the mutations were further subcloned into pFL12
using appropriate restriction enzymes as described previously (Ansari
et al., 2006; Das et al., 2010). The carboxy terminal FLAG
(DYKDDDDK)-tagged GP2 (GP2-FLAG) has been described before
(Das et al., 2010). The GP2-FLAG containing N to A mutation was
further ampliﬁed by using the primers GP2-NheI-For and GP2-FLAG-
NheI-Rev (Table 1) and cloned in a modiﬁed pGEM3 vector which in
addition to T7 RNA polymerase promoter also contains cytomegalo-
virus (CMV) promoter from pCDNA3.1(+) as described (Das et al.,
2010). Mutations in GP3 and GP4 were introduced similarly using
speciﬁc primer (Table 1) and the mutant coding sequences were
transferred to the infectious clone FL12 through the intermediate
vector. Constructs carryingmultiple glycosylation sitemutationswere
generated by fragment exchange using appropriate mutant con-
structs. The plasmid encoding the porcine CD163 has been described
before (Das et al., 2010). Further details of the construction of various
mutants can be obtained from the corresponding author.
Transfection, in vitro transcription, and electroporation
Transfection of plasmids containing genes under T7 RNA poly-
merase promoter was performed using Lipofectamine2000 as de-
scribed before (Ansari et al., 2006; Das et al., 2010). The in vitro
transcripts were generated using mMESSAGE mMACHINE ultra T7 kit
as per the manufacturer's protocol. In vitro transcription reaction and
electroporation of MARC-145 cells was performed as described beforecleotide sequence
ATTCGCCACCATGAAATGGGGTCCATGC
ATGCTCACCGTGAGTTCGAAGG
GCGCCGCCACCATGAAATGGGGTCCATGC
TCTCACTCGAGCTTGTCATCGTCGTCCTTGTAGTCCATCCGTGAGTTCGAAGGAAAAATTGC
GGTCAGCTGTAACCATAG
AGTGTATGCTAGTACTTTG
GGTCAGCTGTAACCATAGTGTATGCTAGTACTTTGAATC
ATTCGCCACCATGGCTAATAGCTGTGC
TCCCTATCGCCGCGCGGC
TAGTAGCGGAATCCGC
AAGGAAAAAGCGCCCCTAAC
ACTCACGGTGGCTTACACGGTG
GGGCTGTGAGTCAAG
GAGGCCGCCACCTTGCC
CGCTATTTCAGCCG
TAGCTGTTTCTTGG
ATTCGCCACCATGGCTGCGCCCCTTC
TCCTCAAATTGCCAGTAAGATG
TCCTCACTTGTCATCGTCGTCCTTGTAGTCAATTGCCAGTAAGATGGCAAAAAAACAGGC
GGCGGTTTTGATGTC
CATCACTGTCACAGCCGCTGTCACAGATG
ACACAGCGCCAAATATC
GTAAAGGCGACACAC
TTCGGAGCCGCCGCCACCATGTTGGGGAGATGCTTGAC
CGAGTTACAGATCTTCTTCAGAAATAAGTTTTTGTTCAAGACGACCCCATTGTTC
CTGTAGGCATAGGCTTG
TTTTTCCTTCGAACTCA CGG
ATCAGGTCGATGGCGG
GTGATATACACGGGTG
CGACTTACCTTTAGAG
nucleotides for mutation of asparagine to alanine are shown in bold.
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roughly 10% of the electroporated cells were separately plated in a 24-
well plate for indirect immunoﬂuorescence to check for the biological
activity of the transfected RNA. The rest of the electroporated cells
were plated in six-well plates for virus recovery.
Viral growth kinetics and plaque assay
Multi-step growth kinetics of wt or various mutant viruses was
performed by infectingMARC-145 cells seeded in a six-well plate with
0.1 MOI of FL12 and glycosylation defective mutant viruses. Due to
signiﬁcantly lower titer of some of the recovered GP3 glycosylation
mutant viruses, an MOI of 0.001 was used. The MARC-145 cells were
infected with the virus following the standard procedure. The cells
were incubated at 37 °C for up to 5 days. The supernatant was
collected at 12 h intervals and virus titers were determined by plaque
assay as described before (Ansari et al., 2006).
Metabolic labeling, immunoprecipitation, and co-immunoprecipitation
(co-IP) assays
Metabolic labeling, immunoprecipitation, and co-IP assays were
performed as reported previously (Ansari et al., 2006; Das et al., 2010).
Appropriate antibodies were used to immunoprecipitate the proteins.
Theproteinswere resolvedbyelectrophoresis in reducinganddenaturing
polyacrylamide gels and the proteins were detected by ﬂuorography as
described previously (Ansari et al., 2006; Das et al., 2010).
Animal experiments and serum neutralization assay
Second or third passagemutant viruses were used in these studies.
These studies were conducted as described previously (Ansari et al.,
2006). Twenty-one-day-old, recently weaned pigs were purchased
from a speciﬁc-pathogen-free herd with a certiﬁed record of absence
of PRRSV infection. All animals were negative for anti-PRRSV
antibodies as tested by ELISA (IDEXX Labs, Portland, ME). Groups of
four pigs were used for each mutant virus. Each group of animal was
housed separately and away from the other groups. The pigs were
intramuscularly injected with wt ormutant viruses with a viral load of
105 TCID50/animal. The serum samples were collected on 0, 7, 14, 21,
35, and 46 days post-inoculation. Serum samples of 7, 14, and 21 days
were used to examine viremia by isolation on MARC-145 cells. All the
serum samples collected on different time points were used to check
neutralizing antibody titer by serum neutralization assay.
The serumneutralization assaywasperformed in96-well cell culture
plates. Serum from each animal was diluted by two-fold serial dilution.
Fixed amount of viruswas incubatedwith diluted serumsamples for 1 h
at 37 C and then used to infectMARC-145 cells. The infectedMARC-145
cells were then incubated for 36 h at 37 °C in cell culture incubator, after
which the cells were ﬁxed and stained for nucleocapsid protein by
SDOW-17 primary antibody. Alexa ﬂuor-488 conjugated goat anti-
mouse IgG antibody was used as secondary antibody.
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